Cathie Wood’s ARK buys Tempus AI stock, sheds Rocket Lab

Cathie Wood’s ARK ETFs have reported their daily trades for Wednesday, March 12th, 2025, with a notable focus on the healthcare and technology sectors. Leading the day’s transactions was a substantial purchase of TEMPUS AI INC (NASDAQ:TEM) shares, with ARK’s flagship innovation fund ARKK acquiring 29845 shares valued at approximately $1,360,335. This move underscores ARK’s continued confidence in the artificial intelligence-driven biotech company, following a pattern of accumulation in recent days.

In the realm of aerospace and defense, ARK’s funds ARKQ and ARKX (NYSE:ARKX) bought a combined total of 7940 shares of AEROVIRONMENT INC (NASDAQ:AVAV), with a total dollar value of $984,560. This purchase comes after a smaller acquisition of the company’s shares just the day before, signaling a growing interest in the unmanned aircraft systems manufacturer.

ARK also increased its stake in the gene-editing space with the purchase of 10671 shares of CRISPR THERAPEUTICS AG (NASDAQ:CRSP) for $452,130 and 18120 shares of INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) for $168,516, spread across its ARKK and ARKG ETFs. These transactions reflect ARK’s ongoing investment in disruptive genomic technologies.

On the sell side, ARK divested a significant number of shares from several companies. The most substantial sale was 41839 shares of ROCKET LAB USA INC (NASDAQ:RKLB), split between ARKQ and ARKX ETFs, with a total dollar value of $745,989. This move suggests a scaling back of ARK’s position in the space launch service provider, a contrast to the buying trend observed with AEROVIRONMENT INC.

Other notable sales included 140707 shares of PRIME MEDICINE INC (NASDAQ:PRME) from ARKK, totaling $267,343, and 9961 shares of CAREDX INC (NASDAQ:CDNA) from ARKG, amounting to $183,282. Additionally, 39431 shares of REPARE THERAPEUTICS INC (NASDAQ:RPTX) were sold through the ARKG ETF for $45,345.

Smaller transactions included the purchase of 1193 shares of IBOTTA INC (NYSE:IBTA) across ARKW and ARKF ETFs, valued at $46,622. This follows a more significant investment in the company earlier in the week, indicating ARK’s sustained interest in the mobile technology firm.

Investors following ARK’s trading activity may find these trends and changes in positions indicative of the fund’s strategic direction, with a clear focus on innovative companies poised for growth in their respective industries.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.